Journal article
Systematic review of the effectiveness of pharmacologic interventions to improve quality of life and well-being in people with dementia
C Cooper, N Mukadam, C Katona, CG Lyketsos, D Blazer, D Ames, P Rabins, H Brodaty, C De Mendonça Lima, G Livingston
American Journal of Geriatric Psychiatry | Published : 2013
Abstract
Objective: To review systematically, for the first time, the effectiveness of all pharmacologic interventions to improve quality of life and well-being in people with dementia. Design: Systematic review and meta-analysis. Methods: We systematically reviewed the 15 randomized controlled trials and one review that fitted predetermined criteria. We included studies that reported the outcomes quality of life, well-being, happiness, or pleasure. Measurements: We rated the validity of studies using a checklist. We calculated mean differences between intervention and control groups at follow-up. Results: None of the evaluated trials reported a significant benefit to quality of life or well-being fo..
View full abstractGrants
Funding Acknowledgements
HB: Grant support/sponsored speaker or advisory board member: NHMRC, Australian Commonwealth Department of Health and Ageing, Pfizer, Eisai, Janssen, Novartis, Lundbeck, Lilly, Medivation, Sanofi, Prana. CGL: Grant support (research or CME): NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, National Football League, Elan; Consultant/Advisor: Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, NFL Players Association, NFL Benefits Office. Honorarium or travel support: Pfizer, Forest, Glaxo-Smith Kline, Health Monitor. CK: Paid lectures and consultancy fees from several pharmaceutical companies including Lilly Lundbeck and Pfizer Eisai; grant funding from Lundbeck. DA: Paid lectures, consultancy fees, advisory board membership and/or support for conference attendance from Eisai, Eli Lilly, Janssen-Cilag, Lundbeck, Novartis and Pfizer, and Prana. PR: legal testimony for Janssen Pharmaceutica, Grant support NIMH, NIA.